The primary objective for BTC Speciality Health is to increase market share through organic growth. New products will continue to be sourced by BioImpact and will enable BTC Speciality Health to expand its product range within pain management and critical care.
Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to announce the successful completion of a challenge study in weaner piglets with its recently developed bromelain-based formulation (BONIFF).
Biomedican has received notification from the US patent office that its 1st patent has been approved and will be issued in the coming months. This is the 1st patent ever to be issued using Yarrowia Lipolytica to produce cannabinoids.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce a research collaboration with Professor Christopher Little and the Raymond Purves Bone and Joint Research Laboratory at the Kolling Institute at Royal North Shore Hospital, Australia.
Bluechiip Limited (ASX:BCT) (FRA:1BL), a developer and leader in wireless tracking solutions for the healthcare and life science, security, defence and manufacturing industries is pleased to release its Appendix 4C - Quarterly Cashflow report and update for the quarter ended 30 June 2021.
Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 30 June 2021 (Q4 FY21), along with the Company's Appendix 4C cash flow report.
Anatara Lifesciences (ASX:ANR), a developer of evidence-based solutions for gastrointestinal diseases in humans and animals, is pleased to announce the transition of Dr David Brookes from Non-Executive Director to Chairman.
